Alexandria Venture Investments, LLC, a 10% owner of TRex Bio, Inc. (TRXB), acquired 178,571 shares of the company's stock on October 13, 2026. The transaction, valued at approximately $2.50 million, was executed at a price of $14.00 per share.
This significant purchase by a major stakeholder is often interpreted as a bullish signal, suggesting confidence in TRex Bio's future performance. The acquisition represents a notable increase in Alexandria Venture Investments' stake in the biopharmaceutical company.
The transaction occurred amidst other recent insider buying activity in TRex Bio, including purchases by entities affiliated with SV Life Sciences Fund VI. These collective insider transactions may indicate a positive sentiment among key investors regarding the company's trajectory.